Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
J Thorac Cardiovasc Surg. 2010 Nov;140(5):1174-80. doi: 10.1016/j.jtcvs.2010.08.012.
Stromal cell-derived factor (SDF)-1α is a potent endogenous endothelial progenitor cell (EPC) chemokine and key angiogenic precursor. Recombinant SDF-1α has been demonstrated to improve neovasculogenesis and cardiac function after myocardial infarction (MI) but SDF-1α is a bulky protein with a short half-life. Small peptide analogs might provide translational advantages, including ease of synthesis, low manufacturing costs, and the potential to control delivery within tissues using engineered biomaterials. We hypothesized that a minimized peptide analog of SDF-1α, designed by splicing the N-terminus (activation and binding) and C-terminus (extracellular stabilization) with a truncated amino acid linker, would induce EPC migration and preserve ventricular function after MI.
EPC migration was first determined in vitro using a Boyden chamber assay. For in vivo analysis, male rats (n = 48) underwent left anterior descending coronary artery ligation. At infarction, the rats were randomized into 4 groups and received peri-infarct intramyocardial injections of saline, 3 μg/kg of SDF-1α, 3 μg/kg of spliced SDF analog, or 6 μg/kg spliced SDF analog. After 4 weeks, the rats underwent closed chest pressure volume conductance catheter analysis.
EPCs showed significantly increased migration when placed in both a recombinant SDF-1α and spliced SDF analog gradient. The rats treated with spliced SDF analog at MI demonstrated a significant dose-dependent improvement in end-diastolic pressure, stroke volume, ejection fraction, cardiac output, and stroke work compared with the control rats.
A spliced peptide analog of SDF-1α containing both the N- and C- termini of the native protein induced EPC migration, improved ventricular function after acute MI, and provided translational advantages compared with recombinant human SDF-1α.
基质细胞衍生因子-1α(SDF-1α)是一种有效的内源性内皮祖细胞(EPC)趋化因子和关键的血管生成前体。重组 SDF-1α 已被证明可改善心肌梗死后的新生血管生成和心功能,但 SDF-1α 是一种体积较大的蛋白质,半衰期较短。小肽类似物可能具有翻译优势,包括易于合成、制造成本低,并且有潜力通过工程生物材料在组织内控制递药。我们假设,通过拼接 N 端(激活和结合)和 C 端(细胞外稳定)并用截短的氨基酸接头将 SDF-1α 的最小化肽类似物设计成,可以诱导 EPC 迁移并在心肌梗死后保留心室功能。
首先使用 Boyden 室测定法在体外测定 EPC 迁移。对于体内分析,雄性大鼠(n=48)进行左前降支冠状动脉结扎。在梗塞时,大鼠随机分为 4 组,并接受梗塞周围心肌内注射生理盐水、3μg/kg 的 SDF-1α、3μg/kg 的拼接 SDF 类似物或 6μg/kg 的拼接 SDF 类似物。4 周后,大鼠进行闭胸压力容积导纳分析。
EPC 置于重组 SDF-1α 和拼接 SDF 类似物梯度中时,迁移明显增加。与对照大鼠相比,在心肌梗死后接受拼接 SDF 类似物治疗的大鼠舒张末期压、每搏量、射血分数、心输出量和每搏功均有显著的剂量依赖性改善。
一种包含天然蛋白的 N 端和 C 端的拼接 SDF-1α 肽类似物可诱导 EPC 迁移,改善急性心肌梗死后的心室功能,与重组人 SDF-1α 相比具有翻译优势。